Full Text View
Tabular View
No Study Results Posted
Related Studies
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
This study is ongoing, but not recruiting participants.
Study NCT01360489   Information provided by XenoPort, Inc.

First Received on May 23, 2011.   Last Updated on April 18, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Sclerosis
Additional conditions recognized in this trial
Muscle Spasticity
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Muscle Hypertonia
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Manifestations
Pathologic Processes
Signs and Symptoms
Interventions listed in this trial
arbaclofen placarbil
Additional drug interventions recognized in this trial
Baclofen
More general drug interventions related to this trial
Central Nervous System Agents
GABA Agents
GABA Agonists
GABA-B Receptor Agonists
Molecular Mechanisms of Pharmacological Action
Muscle Relaxants, Central
Neuromuscular Agents
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
XenoPort, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services